To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...

Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...

Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new ...

Researchers at Helmholtz Munich, the Technical University of Munich and the LMU University Hospital Munich uncovered a mechanism that protects nerve cells from premature cell death, known as ...

Lynk received the green light from the FDA to begin clinical trials of its investigational oral therapy LNK01006 for MS and other diseases.

Researchers have identified how a single mutation in the GPX4 enzyme causes neurons to undergo ferroptosis, leading to severe early-onset dementia.

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

The company has also received orphan drug, rare pediatric disease, and fast-track designations for LTS-101 as a potential treatment for the fatal neurodegenerative disease.

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...